Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Effectiveness of ML-007C-MA in Schizophrenia
NCT07459647Phase 2Recruiting
- Sponsor
- MapLight Therapeutics
- Start
- Mar 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ML-007/PAC in schizophrenia, sponsored by MapLight Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
ML-007/PAC
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07459647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459647.